Phase 2
Within the next six years, the multiple myeloma market is projected to be $37.5 billion – an incredible growth of $30 billion since 2015, when the market was valued at about $7.5 billion.
On April 5, San Francisco’s Eidos Therapeutics closed on a Series B financing round worth $64 million. Now the company has filed with the U.S. Securities and Exchange Commission (SEC) to raise $115 million through an initial public offering (IPO).
After Axovant Sciences’ spectacular clinical trial failure in September 2017, the company has been reorganizing. Today it announced it had completed that reorganization by adding to its executive team and Scientific Advisory Board.
Genmab A/S, and Johnson & Johnson’s Janssen division have pulled the plug on the Phase Ib/II trial of daratumumab in combination with Roche’s Tecentriq.
It’s been a busy month for IPOs. Numerous biotech companies announced their intentions to publicly list their stock on an exchange in the U.S. or abroad in order to gain new funding to advance developmental programs.
One month after Prothena Corporation shuttered its NEOD001 program for AL amyloidosis following a Phase IIb failure, the company initiated a reorganization that includes a workforce reduction of 57 percent.
Weeks after securing $52 million in a Series C financing, Magenta Therapeutics is eying the raising of $100 million in an initial public offering two years after it was launched by Third Rock Ventures and Atlas Venture with $48.5 million in Series A financing.
There are dollar signs in the treatment of nonalcoholic steatohepatitis (NASH). The market is pegged to hit $25 billion by 2026 and companies are flooding the developmental pipeline with potential treatments for a disease that has no approved therapies in the United States.
A day after Illinois-based Aptinyx strengthened its relationship with pharma giant Allergan, the company is now eying an $80 million initial public offering of stock on the Nasdaq Exchange.
Hemophilia B patients have some good news to cheer. Data suggests that uniQure’s AAV5 gene therapy may be viable treatments for 97 percent of patients. However, uniQure wasn’t the only company touting positive news in the treatment of hemophilia.
PRESS RELEASES